BofA/Merrill Lynch Starts Aimmune Therapeutics (AIMT) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Trump threatens to bomb Oman over Iran stance
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
Credit Suisse Starts Aimmune Therapeutics (AIMT) at Outperform
August 31, 2015 7:12 AM EDTCredit Suisse initiates coverage on Aimmune Therapeutics (NASDAQ: AIMT) with a Outperform rating and a price target of $44.00.
Analyst V. Divan commented, "We see AIMT as one of the leaders in developing treatments to help manage life-threatening food allergies, with... More
Piper Jaffray Starts Aimmune Therapeutics (AIMT) at Overweight
August 31, 2015 6:27 AM EDTPiper Jaffray initiates coverage on Aimmune Therapeutics (NASDAQ: AIMT) with a Overweight rating and a price target of $35.00, leading data in peanut allergy.
Analyst Charles Duncan commented, "Aimmune is leveraging its broadly applicable oral immunotherapy (OIT) platform to develop proprietary products aimed at protecting patients... More
